Nearly half of prostate cancer patients who undergo radical prostatectomy with curative intent will see their disease return — and the Phase 3 PROTEUS trial just produced the most statistically striking argument yet for intervening before and after that surgery rather than waiting. In 2,109 patients with high-risk localized or locally advanced disease, adding apalutamide to androgen deprivation therapy for six months perioperatively made patients nine times more likely to have little or no residual cancer at surgery — a complete pathological response or minimal residual disease rate of 8.9% versus 1.0% on hormonal therapy alone.
The second co-primary endpoint matters more to long-term outcomes: a 20% reduction in the risk of metastasis or death (HR 0.80; 95% CI 0.67–0.96; p=0.02), with five-year metastasis-free survival of 78.2% versus 73.5%. Both endpoints were evaluated by blinded independent central review, which matters because pathological response assessments at a surgical margin are notoriously susceptible to site-level variability. Median follow-up was 61.7 months — long enough to trust the metastasis-free survival curve rather than lean on a surrogate. The trial also pushed time to subsequent therapy beyond six years in the apalutamide arm, a figure that carries real weight in a disease where treatment sequencing determines whether curative options remain available.
The design itself is the strategic argument. Standard of care for this population has been surgery or radiotherapy, full stop, with systemic intensification reserved for recurrence. PROTEUS inverts that logic by treating the perioperative window as the highest-leverage intervention point — before micrometastatic disease escapes local control and before the disease state becomes formally incurable. The data were selected to open the plenary session at ASCO 2026 and were published simultaneously in the New England Journal of Medicine, a pairing that signals the field’s appetite for a paradigm revision rather than an incremental update.
The regulatory consequence to track is whether the FDA acts on these data to extend apalutamide’s label into the perioperative localized setting — a population that dwarfs the metastatic contexts where the drug currently operates. Label expansion into earlier, larger patient pools is where commercial trajectories get redrawn, and the strength of both co-primary endpoints here gives regulators little statistical reason to hesitate.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
